Clinical Assessment of the Flash - Eye Movement Desensitization and Reprocessing (Flash-EMDR)

January 3, 2023 updated by: Paul Ritvo, York University

Clinical Assessment of the Flash Version of Eye Movement Desensitization and Reprocessing in Memory Distress: A Double Blinded Randomized Controlled Trial

To assess the Flash version of EMDR in reductions of the disturbance of upsetting memories at post-intervention, and 1-month follow up within a double-blinded, online 2-arm randomized controlled trial (RCT) with self-report outcomes. We will assess 45 per group, adequate for the detection of a medium effect size.

This double-blinded, RCT will assess the comparative efficacy of these two online interventions designed to reduce memory disturbance.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This double-blinded, RCT compares the efficacy of 2 online interventions (Flash Version - EMDR; EMDR alone) designed to reduce memory disturbance.Inclusion Criteria: (1) approved for engagement assessment by the CloudResearch platform; (2) 25-60 years; 3) US-Canada residence; (4) a recalled disturbing memory of an event that has not repeated and was moderately upsetting, or greater when event occurred; (5) memory remains moderately upsetting or greater on recall. The disturbance of upsetting memories at post-intervention, and 1-month follow up will be assessed with self-report outcomes. We will assess 45 / group, adequate for the detection of a medium effect size. linked to an earlier memory (that is equally or more disturbing). Exclusion Criteria: Diagnosis of: (1) bipolar disorder; (2) borderline personality disorder; (3) obsessive compulsive disorder; (4) schizophrenia; (5) substance abuse/addiction in the past 3 months; (6) any suicidal ideation; (7) suicide attempt in the past 6 months. Interventions: Experimental participants observe video instructions of full FT, while controls receive an online intervention that follows traditional EMDR. Measures: Primary outcome: State Anxiety subscale of the State Trait Anxiety Inventory (STAI) at baseline, post-intervention, and after 1-month follow up; Post Traumatic Stress Disorder symptoms (PTSD) measured by PCL-5 (1 month follow up).

Secondary outcomes: the Subjective Units of Disturbance (SUDs) assessing change in immediately reported disturbance of recalled memories (baseline and post-intervention); depression measured by Patient Health Questionnaire (PHQ9) and Positive-Negative Affect measured by the Positive and Negative Affect Scale (PANAS).

Study Type

Interventional

Enrollment (Anticipated)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M3J 1P3
        • Recruiting
        • York University
      • Toronto, Ontario, Canada, M4E 3C1
        • Recruiting
        • York University - School of Kinesiology and Health Science
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Moderately upsetting or > memory of an event that occurred > 2 years ago and has since not repeated
  • Moderately upsetting or > memory remains moderately upsetting when recalled
  • Memory is not tied to an earlier memory that is equally disturbing or >

Exclusion Criteria:

  • Bipolar Disorder
  • Borderline Personality Disorder
  • Obsessive-Compulsive Disorder
  • Schizophrenia
  • Substance Abuse/Addiction in past 3 months
  • Suicidal ideation or attempted suicide in the past 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Flash Version of EMDR
Flash methods (e.g. positive engaging focus) are used in addition to the standard EMDR techniques conveyed by video viewed online
EMDR and the inclusion of a positive engaging focus generated autonomously by participant
Active Comparator: EMDR - alone
Use of standard EMDR techniques conveyed by video online
EMDR and the inclusion of a positive engaging focus generated autonomously by participant

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PTSD Checklist for DSM-5 (PCL-5) 1 - 44
Time Frame: 1 month follow up
Self Report Questionnaire
1 month follow up
State-Trait Anxiety Inventory - State 0 - 80.
Time Frame: 1 month follow up
Self Report Questionnaire
1 month follow up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Health Questionnaire 0 - 27
Time Frame: 1 month follow up
Self Report Questionnaire
1 month follow up
Positive and Negative Affect Schedule 20 - 100
Time Frame: 1 month followup
Self Report Questionnaire
1 month followup

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2021

Primary Completion (Anticipated)

March 1, 2023

Study Completion (Anticipated)

March 1, 2023

Study Registration Dates

First Submitted

December 29, 2021

First Submitted That Met QC Criteria

February 26, 2022

First Posted (Actual)

March 2, 2022

Study Record Updates

Last Update Posted (Estimate)

January 4, 2023

Last Update Submitted That Met QC Criteria

January 3, 2023

Last Verified

February 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 2021-141

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

Upon request, an anonymized data sheet (excel) will be sent

IPD Sharing Time Frame

Within 1 month of request

IPD Sharing Access Criteria

Investigator at recognized academic or clinical institution

IPD Sharing Supporting Information Type

  • Study Protocol
  • Statistical Analysis Plan (SAP)
  • Informed Consent Form (ICF)
  • Clinical Study Report (CSR)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on PTSD

Clinical Trials on Flash Version of EMDR

3
Subscribe